Goldman Sachs
IMGN

Goldman Sachs’s Immunogen Inc IMGN Stock Holding History

Goldman Sachs’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,189,485
Closed -$35.3M – 6006
2023
Q4 		$35.3M Sell
1,189,485
-49,614
-4% -$988K 0.01% 1426
2023
Q3 		$19.7M Sell
1,239,099
-372,003
-23% -$6.19M ﹤0.01% 1813
2023
Q2 		$30.4M Sell
1,611,102
-602,717
-27% -$7.12M 0.01% 1495
2023
Q1 		$8.5M Sell
2,213,819
-429,450
-16% -$1.83M ﹤0.01% 2565
2022
Q4 		$13.1M Buy
2,643,269
+1,578,901
+148% +$8.56M ﹤0.01% 2328
2022
Q3 		$5.09M Buy
1,064,368
+217,249
+26% +$1.15M ﹤0.01% 3119
2022
Q2 		$3.81M Buy
847,119
+167,137
+25% +$726K ﹤0.01% 3431
2022
Q1 		$3.24M Sell
679,982
-331,505
-33% -$1.84M ﹤0.01% 3776
2021
Q4 		$7.51M Sell
1,011,487
-289,023
-22% -$1.8M ﹤0.01% 3031
2021
Q3 		$7.37M Sell
1,300,510
-57,493
-4% -$332K ﹤0.01% 3011
2021
Q2 		$8.95M Sell
1,358,003
-1,237,996
-48% -$8.64M ﹤0.01% 2796
2021
Q1 		$21M Sell
2,595,999
-24,646
-0.9% -$201K 0.01% 1889
2020
Q4 		$16.9M Buy
2,620,645
+1,686,429
+181% +$9.84M ﹤0.01% 2005
2020
Q3 		$3.36M Sell
934,216
-787,340
-46% -$3.18M ﹤0.01% 3199
2020
Q2 		$7.92M Buy
1,721,556
+724,894
+73% +$3.08M ﹤0.01% 2441
2020
Q1 		$3.4M Buy
996,662
+118,669
+14% +$519K ﹤0.01% 2938
2019
Q4 		$4.48M Buy
877,993
+453,012
+107% +$1.54M ﹤0.01% 3044
2019
Q3 		$1.03M Sell
424,981
-707,895
-62% -$1.88M ﹤0.01% 4011
2019
Q2 		$2.46M Sell
1,132,876
-423,128
-27% -$1M ﹤0.01% 3396
2019
Q1 		$4.22M Buy
1,556,004
+332,723
+27% +$1.44M ﹤0.01% 3109
2018
Q4 		$5.87M Sell
1,223,281
-85,909
-7% -$521K ﹤0.01% 2744
2018
Q3 		$12.4M Sell
1,309,190
-321,140
-20% -$3.09M ﹤0.01% 2290
2018
Q2 		$15.9M Buy
1,630,330
+627,399
+63% +$6.61M ﹤0.01% 2068
2018
Q1 		$10.6M Buy
1,002,931
+697,564
+228% +$6.89M ﹤0.01% 2281
2017
Q4 		$1.96M Buy
305,367
+173,797
+132% +$1.07M ﹤0.01% 3817
2017
Q3 		$1.01M Sell
131,570
-437,098
-77% -$2.9M ﹤0.01% 4564
2017
Q2 		$4.04M Sell
568,668
-19,876
-3% -$90.9K ﹤0.01% 3240
2017
Q1 		$2.28M Sell
588,544
-38,719
-6% -$113K ﹤0.01% 3615
2016
Q4 		$1.28M Sell
627,263
-16,981
-3% -$34.1K ﹤0.01% 4243
2016
Q3 		$1.73M Buy
644,244
+118,132
+22% +$344K ﹤0.01% 3954
2016
Q2 		$1.62M Buy
526,112
+437,445
+493% +$2.74M ﹤0.01% 3793
2016
Q1 		$756K Buy
88,667
+16,684
+23% +$141K ﹤0.01% 4331
2015
Q4 		$977K Sell
71,983
-19,322
-21% -$238K ﹤0.01% 4326
2015
Q3 		$877K Sell
91,305
-69,521
-43% -$1.02M ﹤0.01% 4606
2015
Q2 		$2.31M Sell
160,826
-55,344
-26% -$608K ﹤0.01% 3697
2015
Q1 		$1.94M Sell
216,170
-10,101
-4% -$73.2K ﹤0.01% 3815
2014
Q4 		$1.38M Buy
226,271
+7,493
+3% +$68.5K ﹤0.01% 4226
2014
Q3 		$2.32M Buy
218,778
+140,661
+180% +$1.59M ﹤0.01% 3800
2014
Q2 		$926K Buy
78,117
+1,722
+2% +$21.6K ﹤0.01% 4762
2014
Q1 		$1.14M Sell
76,395
-3,402
-4% -$53.6K ﹤0.01% 4543
2013
Q4 		$1.17M Sell
79,797
-5,243
-6% -$80.6K ﹤0.01% 4588
2013
Q3 		$1.45M Buy
85,040
+8,454
+11% +$149K ﹤0.01% 4229
2013
Q2 		$1.27M Buy
+76,586
New +$1.24M ﹤0.01% 4174

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's IMGN Position: Q1 2024 in Review

Goldman Sachs sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 1,189,485 shares — an estimated $35.3M sold.

Goldman Sachs first reported a position in IMGN in Q2 2013 and held it in 43 quarters. The position peaked at $35.3M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Goldman Sachs reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Goldman Sachs sold 1,189,485 Immunogen Inc shares in Q1 2024, an estimated $35.3M.
  • Goldman Sachs first reported a position in Immunogen Inc in Q2 2013 and held it in 43 quarters.
  • Goldman Sachs's Immunogen Inc position peaked at $35.3M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.